mCRPC Treatment VL

UPWARD Study - Seizure Rates in Enzalutamide-Treated Men with mCRPC - Susan Slovin

Details
(Length of presentation: 17 min) Alicia Morgans, MD discusses the UPWARD Study with Susan Slovin, MD, PhD. A study Dr. Slovin was a part of conducting to answer the question “Are seizure rates affected by treatment with enzalutamide in patients with metastatic castration-resistant prostate cancer who have seizure risk factors?” Dr. Slovin discusses with Dr. Morgans the reasons for conducting the U...

Sequencing and Combining CRPC Therapies: What Does the Future Hold? - Charles Ryan

Details
Sequencing and Combining CRPC Therapies: What Does the Future Hold? Presentation from the 2017 Annual LUGPA meeting in Chicago, IL (Length of Presentation: 21 min) Dr. Charles Ryan provides a comprehensive overview of CRPC including the natural history of prostate cancer and the many sequences that exist in the treatment of the disease. Dr. Ryan states that CRPC is a broad-spectrum condition so it...

Impacts of Latitude and Stampede: Urologist and Urologic Oncologist's Perspective

Details
(Length of lecture ~ 36 minutes) Alicia Morgans hosts a discussion with David Penson, Charles Ryan and Neal Shore regarding impacts of LATITUDE and STAMPEDE data from a urologist and urologic oncologists perspective, taking in to account the recently updated data from the CHAARTED trial. Specifically, discussed was treating patients that have high-volume, aggressive metastatic prostate cancer that...

Clinical Conversation: CHAARTED, LATITUDE and STAMPEDE

Details
(Length of discussion ~ 27 minutes) Charles Ryan hosts a discussion with Alicia Morgans and Christopher Sweeney regarding data from the LATITUDE, STAMPEDE and CHAARTED trials, and the survivor endpoints for patients receiving initial androgen deprivation therapy (ADT) for metastatic prostate cancer. Specifically, discussed is the interface of these three very important studies and the many treatme...

STAMPEDE and LATITUDE Trials: Issues to Consider - Thomas Keane

Details
Biograhy: Thomas E. Keane Related Content: LATITUDE abstract from ASCO 2017 STAMPEDE abstract from ASCO 2017 STAMPEDE - Clinical Trial Information A Clinical Conversation with Alicia Morgans and Charles Ryan: Considerations of ASCO 2017 LATITUDE and STAMPEDE Crashing into progress: New findings meet old habits

A Clinical Conversation with Alicia Morgans and Charles Ryan: Considerations of ASCO 2017 LATITUDE and STAMPEDE

Details
Clinical Considerations of ASCO 2017 relating to LATITUDE and STAMPEDE Biographies: Alicia Morgans, MD, MPH Charles J. Ryan, MD Related Content: LATITUDE abstract from ASCO 2017 STAMPEDE abstract from ASCO 2017 STAMPEDE - Clinical Trial Information Video Lecture on LATITUDE and STAMPEDE Trials

Preliminary Data from the PROCEED Registry- Oliver Sartor

Details
Overall Survival Analysis of African Americans and Caucasian Patients Receiving Sipuleucel-T: Preliminary Data from the PROCEED Registry Read the Abstract Biographies: E. David Crawford Oliver Sartor is the only medical oncologist in Louisiana specializing in the treatment of prostate cancer patients. Dr. Sartor, the Laborde Professor of Cancer Research in the Medicine and Urology Departments of T...

Bone Targeted Therapy with Zoledronate or Denosumab is Required in Men with mCRPC Responding to Anticancer Therapy - Noel Clarke

Details
Access to all Advanced Prostate Cancer Consensus Conference Video Coverage Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer

Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer- Karim Fizazi

Details
The following presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October. Karim Fizazi, MD presents, “Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer” and discusses mechanisms of resistance to ADT with CRPC, mechanisms of CRPC resistance to new drugs and mechanisms of resis...

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide in the High-risk Nonmetastatic Castration-resistant Prostate Cancer - Charles Ryan

Details
Journal Club: Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. European Urology Charles Ryan, MD discusses the androgen receptor antagonist apalutamide was safe in patients with high-risk nonmetastatic castration-resistant prostate cancer and, based on dura...